Form 4: Kyntra Bio Director Michael Kauffman Receives Stock Options

Director Michael Kauffman was granted 7,000 stock options in Kyntra Bio, Inc. as part of a standard equity compensation plan.

Summary

• Director Michael Kauffman acquired 7,000 stock options in Kyntra Bio, Inc. (KYNB) on June 12, 2026.
• The options have an exercise price of $7.13 per share.
• The options are set to expire on June 11, 2036.
• The grant vests in four equal quarterly installments starting from the date of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $7.13 exercise price.

Future Outlook

The options vest in four equal quarterly installments, indicating a one-year vesting schedule for the director's equity award.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of quarterly vesting schedules is consistent with standard equity compensation practices for board members in small-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of the 7,000 options in four equal quarterly installments.

Key Dates

Keywords

Kyntra Bio, KYNB, Form 4, Insider Trading, Stock Options, Director Compensation